Innovative retatrutide, a twin -action medication targeting both GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Preliminary clinical trials have shown significant decreases in body size and improvements in health markers for individuals with obesity . Scientists believe this ground-breaking approach cou